OncoDaily

JJ Singleton, Research Advocate at Fight Colorectal Cancer, adolescent and young adult (AYA) cancer survivor, shared on LinkedIn: “This week has had procedures and spirals for me personally: It’s had tough news for many friends in the cancer world It’s had us as a society losing absolute icons and people that brought us so much joy and made the world at large better It’s had unimaginable natural disasters, and the forming of potential others It’s seen politicians continue to do dumb things...

Neoadjuvant therapy has changed more than the timing of systemic treatment in early breast cancer. It provides an opportunity to observe tumor sensitivity in vivo, and the amount of residual disease identified at surgery has become an increasingly important determinant of prognosis and post-neoadjuvant treatment. Pathologic complete response, particularly in triple-negative and HER2-positive breast cancer, remains one of the most clinically informative markers of treatment sensitivity.

The success of targeted therapy in metastatic ALK-positive non-small-cell lung cancer created an intuitive expectation: if ALK inhibition can profoundly suppress advanced disease, perhaps the same strategy should eradicate microscopic residual disease after surgery. E4512 shows why that assumption cannot be taken for granted.

Barbara Jereczek-Fossa, Full Professor of Radiation Oncology at Milan University, Chair of Radiation Oncology at the European Institute of Oncology, Milan, Italy, President of ESTRO, shared on LinkedIn: “European Society for Radiotherapy and Oncology (ESTRO) Meets Asia 2026 has come to a close, an inspiring meeting full of science, exchange and new connections.

Conquer Cancer, the ASCO Foundation shared on LinkedIn: “Early in her career, medical oncologist and past Conquer Cancer grant recipient Dr. Jennifer Ligibel realized that breast cancer patients wanted to be active participants in their own recovery. This insight launched her 20-year research journey, culminating in her leadership of the landmark BWEL trial.

“Life is not easy for any of us. But what of that? We must have perseverance and above all confidence in ourselves. We must believe that we are gifted for something and that this thing must be attained.” – Marie Curie Historically, women were excluded from or denied the opportunity to practice science. Yet, even within these constraints, some of the greatest achievements in science owe much to women.

Zacharoula Sidiropoulou, Senior Consultant Breast Surgical Oncologist at Hospital São Francisco Xavier, shared on LinkedIn: “Today I’ll be joining the OncoDaily Community Oncology Global Congress 2026 for a conversation on something I care deeply about: Value-Based Cancer Care and Real-World Evidence: Measuring Outcomes That Matter We talk a lot about value in cancer care, though behind the indicators, dashboards and models, there is a much simpler issue: Are we measuring what really matters...

The Max Foundation shared on LinkedIn: “Across Latin America, we work alongside local patient organizations that help people living with cancer and rare diseases such as chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), gastrointestinal stromal tumor (GIST), and acute lymphoblastic leukemia (ALL). Our partnerships strengthen support networks and help patients navigate challenges beyond access to treatment through: Patient Advocacy Peer Support Education Patient Navigation.

Paul Chilwesa, Board Member of Madison Life Insurance Company Zambia Limited – MLife, shared on LinkedIn: “During our conversations with health leaders and experts at the World Health Organization African Region RC76 one operational reality consistently came to the fore: we cannot shift cancer survival curves across the continent while early diagnosis remains confined to tertiary hospitals. The front line must move directly to Primary Health Care (PHC).

Parker Institute for Cancer Immunotherapy (PICI) shared on LinkedIn: “Earlier this month, PICI CEO Karen Knudsen MBA PhD joined California lawmakers for a hearing on the role of artificial intelligence in life sciences, sharing how AI can help accelerate progress against cancer and address long-standing gaps in the healthcare system.